Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding

About this update from Plus Therapeutics, Inc.

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company focused on central nervous system ("CNS") cancers, today provides a comprehensive business update. Notably, the Company announces it is changing its company name from Plus Therapeutics to Cerenome and Nasdaq ticker to CNSY, effective August 3, 2026. Furthermore, the Company affirmed its anticipated 2026 milestones guidance, including commercial guidance around its CNSide Diagnostics business unit. Plus will host a business update conference call and webcast today at 8:30 a.m. Eastern time to discuss the rebranding, progress to milestones and provide additional detail on the Company's progress for CNSide® Diagnostics. REYOBIQ™, and its artificial intelligence strategy. In connection with the rebrand, the Company expects its common stock to begin trading on Nasdaq under the new ticker symbol "CNSY". Shareholders are not required to take any action in connection with the anticipated name and ticker change. The Company expects its new corporate website, cerenome.com, to launch in connection with the ticker change. "During the first half of 2026, we remained steadfastly focused on priorities outlined at the beginning of the year, specifically advancing REYOBIQ toward pivotal-trial readiness, scaling CNSide commercialization and building the data infrastructure that inter-connects and fully leverages our therapeutic and diagnostic platforms," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "The Cerenome identity change is the capstone of months of planning reflecting the Company's current de facto identity as an integrated CNS oncology platform company designed to combine therapeutic interventions, diagnostic insights and advanced data analytics for physicians to improve outcomes for patients with CNS cancers and create long-term value for stockholders." Business Update Conference Call and Webcast A replay of the webcast will be available following the event in the Investor Relations section of the Company's website. Corporate Rebrand to Cerenome Plus is introducing the Cerenome corporate identity to better reflect t...

View stock analysis, news, and events for Plus Therapeutics, Inc.